|

Octreotide LAR Clinical Trials

1 actively recruiting trial across 1 location

Also known as: SOM230

Pipeline

Phase 3: 1

Top Sponsors

  • Novartis Pharmaceuticals1

Indications

  • Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)1
  • Somatostatin Receptor Positive (SSTR+)1
  • Cancer1

Scottsdale, Arizona1 trial

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Mayo Clinic Arizona

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.